Effects of dynorphin fragments on learning and memory impairment induced by carbon monoxide exposure and β-amyloid peptide (25-35) in mice

被引:0
|
作者
Hiramatsu, M [1 ]
Inoue, K [1 ]
Kameyama, T [1 ]
机构
[1] Meijo Univ, Fac Pharmaceut Sci, Dept Chem Pharmacol, Nagoya, Aichi 4688503, Japan
关键词
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The anti-amnesic effects of dynorphins on beta-amyloid peptide-(25-35)- and carbon monoxide (CO)-induced impairment of learning and/or memory in mice were investigated using a Y-maze task and a passive avoidance rest. Administration of beta-amyloid peptide-(25-35) or CO intoxication induced a decrease in both alternation behavior and latency in passive avoidance tests. Dynorphin A-(1-13) and A-(2-13) (0.5 and/or 1.5 nmol/mouse, i.c.v.) improved the beta-amyloid peptide-(25-35)- and GO-induced impairment of alternation performance and shortened the step-down latency. Nor-binaltorphimine (nor-BNI) (4.9 nmol/mouse, i.c.v.) partially blocked the effects of dynorphin A-(1-13), but did not block the effects of dynorphin A-(2-13) on the beta-amyloid peptide-(25-35)- and GO-induced impairment of learning and/or memory. These results indicate that dynorphin fragments improve delayed amnesia induced by beta-amyloid peptide-(25-35) and CO via not only kappa opioid receptors, but also "non-opioid" mechanisms.
引用
收藏
页码:117 / 118
页数:2
相关论文
共 50 条
  • [1] Effect of Cilostazol on Learning and Memory Impairment Induced by β Amyloid Peptide (25-35) in Mice
    Takiguchi, Osanao
    Mori, Hiromasa
    Nishiyama, Aki
    Nabeshima, Toshitaka
    Hiramatsu, Masayuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 88P - 88P
  • [2] Effects of Hericium erinaceus on amyloid β(25-35) peptide-induced learning and memory deficits in mice
    Mori, Koichiro
    Obara, Yutaro
    Moriya, Takahiro
    Inatomi, Satoshi
    Nakahata, Norimichi
    BIOMEDICAL RESEARCH-TOKYO, 2011, 32 (01): : 67 - 72
  • [3] Improvement of melatonin on learning and memory impairment induced by amyloid β-peptide 25-35 in elder rats
    Shen, YX
    Wei, W
    Yang, J
    Liu, C
    Dong, C
    Xu, SY
    ACTA PHARMACOLOGICA SINICA, 2001, 22 (09): : 797 - 803
  • [4] Protective effects of xanthoceraside on learning and memory impairment induced by Aβ25-35 in mice
    Chi, Tian-Yan
    Wang, Li-Hua
    Qu, Chan
    Yang, Bai-Zhen
    Ji, Xue-Fei
    Wang, Yi
    Okuyama, Toru
    Yoshihito, Okada
    Zou, Li-Bo
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2009, 11 (12) : 1019 - 1027
  • [5] Effects of liquiritigenin treatment on the learning and memory deficits induced by amyloid β-peptide (25-35) in rats
    Liu, Rui Ting
    Zou, Li Bo
    Fu, Jie Ying
    Lu, Qiu Jun
    BEHAVIOURAL BRAIN RESEARCH, 2010, 210 (01) : 24 - 31
  • [6] Protective effects of compound FLZ onβ-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment
    Fang FANG Geng-tao LIU~2 Department of Pharmacology
    Acta Pharmacologica Sinica, 2006, (06) : 651 - 658
  • [7] Protective effects of compound FLZ on β-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment
    Fang, Fang
    Liu, Geng-Tao
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (06) : 651 - 658
  • [8] Effects of baicalein on β-amyloid peptide-(25-35)-induced amnesia in mice
    Wang, SY
    Wang, HH
    Chi, CW
    Chen, CF
    Liao, JF
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 506 (01) : 55 - 61
  • [9] Effects of resveratrol on the impairment of learning and memory in mice after injection of Aβ25-35
    Omi, Ayano
    Nomura, Tomohiro
    Ibi, Daisuke
    Mamiya, Takayoshi
    Hiramatsu, Masayuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S139 - S139
  • [10] Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β-amyloid peptide (25-35)-induced memory impairment in mice
    Takahashi, Junpei
    Ueta, Yudai
    Yamada, Daisuke
    Sasaki-Hamada, Sachie
    Iwai, Takashi
    Akita, Tomomi
    Yamashita, Chikamasa
    Saitoh, Akiyoshi
    Oka, Jun-Ichiro
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2022, 42 (04) : 492 - 501